Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate. Imeglimin has already completed phase 2 clinical trials in type 2 diabetes patients in the US and EU and is ready for Phase III.
This innovative compound is the first of a new class of oral antidiabetic agents called “glimins“. It basically decreases mitcohondrial respiration, meaning that it targets the key defect associated with all three organs implicated in type II diabetes. Clinical studies to date have proven Imeglimin to have an efficiency comparable to Metformin, the golden standard treatment. Imeglimin, however, has a better safety/tolerability profile and doesn’t induce patient resistance, which Metformin unfortunately does.
The current phase 1 study in Japan was conducted with a design comparable to the previous one performed on Caucasian subjects. Overall, the results indicate that Imeglimin exhibits an excellent safety profile and pharmacokinetics in Japanese subjects, similar to results previously achieved in subjects in the US and EU.